Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 known ✓ | Q13639 | 11/20 | 0.52 |
| ▸ | KCNH2 known ✓ | Q12809 | 5/20 | 0.51 |
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.51 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.51 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.51 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.51 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.51 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.51 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.51 |
| ▸ | KMT2A known ✓ | Q03164 | 1/20 | 0.51 |
| ▸ | DRD2 known ✓ | P14416 | 2/20 | 0.45 |
| ▸ | DRD3 | P35462 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | DRD4 | P21917 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL1502129 | 1.00 | HTR4 (0.52) | HTR4KCNH2DRD3MEN1LMNA | |
| SCHEMBL1501911 | 0.96 | HTR4 (0.56) | HTR4KCNH2DRD3MEN1LMNA | |
| SCHEMBL1502208 | 0.88 | HTR4 (0.66) | HTR4KCNH2DRD3MEN1LMNA | |
| SCHEMBL1502271 | 0.87 | KCNH2 (0.67) | HTR4KCNH2DRD3MEN1LMNA | |
| SCHEMBL1502011 | 0.87 | KCNH2 (0.67) | HTR4KCNH2DRD3MEN1LMNA | |
| SCHEMBL1502283 | 0.86 | KCNH2 (0.56) | HTR4KCNH2DRD3MEN1LMNA | |
| SCHEMBL1502171 | 0.86 | KCNH2 (0.59) | HTR4KCNH2DRD3MEN1LMNA | |
| SCHEMBL1502057 | 0.85 | KCNH2 (0.51) | HTR4KCNH2DRD3MEN1LMNA | |
| SCHEMBL1502276 | 0.83 | HTR4 (0.57) | HTR4KCNH2DRD3MEN1LMNA | |
| Fumaric Acid SCHEMBL1502280 | 0.82 | KCNH2 (0.61) | HTR4KCNH2DRD3MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7906510-B2 | Amide derivative and pharmaceutical composition containing the same | Dainippon Sumito Pharma Co., Ltd. (JP) | 2011-03-15 | — | — | US | disclosed |
| US-20100249399-A1 | AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Sumitomo Pharma Co., Ltd. (JP) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249399-A1 | AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | HTR4, MC2R, HTR1D | HTR4 1/4885KCNH2 4145/4885MEN1 1304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.